一项新的2027年规则允许30-65名妇女每5年在家中接受一次由保险覆盖的HPV检测,以改善子宫颈癌筛查服务。 A new 2027 rule lets women 30–65 use at-home HPV tests every 5 years, covered by insurance, to improve cervical cancer screening access.

2027年1月生效的一项新的联邦准则允许30至65岁的妇女每五年选择一次在家里自行收集的高危险HPV测试,由私人保险负担费用。 A new federal guideline effective January 2027 allows women aged 30 to 65 to choose a self-collected at-home high-risk HPV test every five years, with private insurance covering the cost. 这项测试于2025年5月获得FDA批准,为帕普检查提供了一个方便而准确的替代方案,该检查仍被建议每三年对21岁至29岁的女性进行一次. The test, FDA-approved in May 2025, offers a convenient, accurate alternative to Pap smears, which remain recommended for women 21 to 29 every three years. 改革旨在通过减少排期、不适和准入问题等障碍,提高筛查率,特别是在服务不足的地区。 The change aims to boost screening rates by reducing barriers like scheduling, discomfort, and access issues, especially in underserved areas. 早期发现至关重要,因为早期发现子宫颈癌时极易治疗,其存活率为90%,为五年,但晚期则降至20%。 Early detection is critical, as cervical cancer is highly treatable when caught early, with a 90% five-year survival rate, but drops to 20% at later stages. 尽管50多年来病例减少了50%,但约一半的被确诊妇女从未接受过检查,或早该接受检查。 Despite a 50% decline in cases over 50 years, about half of diagnosed women have never been screened or are overdue. 最新资料支持以病人为中心的护理,并通过提供更广泛的服务改善成果。 The update supports patient-centered care and improved outcomes through broader access.